

Department of Pathology Li Ka Shing Faculty of Medicine The University of Hong Kong

## HKU Discovers that Antioxidants Lead to Growth in Liver Cancer Cells

February 18, 2016



## **Speakers**

### **Professor Irene Oi-Lin Ng**

Loke Yew Professor in Pathology Chair Professor and Head Department of Pathology Director, State Key Laboratory for Liver Research

### Dr Carmen Chak-Lui Wong

Assistant Professor Department of Pathology

### **Miss Iris Ming-Jing Xu**

PhD Candidate Department of Pathology




## Liver cancer – Huge epidemiological impact

LIVER CANCER Mortality rate per 100,000, both sexes

55% of all new liver cancer cases worldwide (500,000 - 600,000 cases/ year) occur in China

2nd commonest fatal cancer in China; 3<sup>rd</sup> in HK





Cirrhotic liver



Pre-malignant

Dysplastic nodule



HCC

Malignant




Metastatic HCC

3



## Liver Cancer & Hepatitis B Virus (HBV)




#### HBsAg carrier prevalence

- □ <1%
- 1-5%
- 5-10%
- >10%
- Poorly documented or not known

10% of the Hong Kong population are HBV carriers



## Liver Cancer & Hepatitis B Virus (HBV)




Geographic variation: Striking correspondence between areas where HCC is common and areas where HBV is prevalent



## **Hepatitis B virus**

- Transmission through blood/body fluid
- Maternal transmission for HBV




- Causes carrier state, acute and chronic hepatitis or end-stage liver
- Casual relationship with liver cancer

Vaccine available for HBV



### Liver cancer



## >80% of liver cancer patients are HBV carriers



## **Liver cancer - challenges**

## Treatment far from perfect!

No patient stratification for treatment "One-size-fits-all"

**Molecular drugs** The only FDA-approved Sorafenib has modest effect

Health care burden


#### Resistant to chemodrugs Resistant to conventional chemotherapy

#### **Social impact**

Peak age of patients: 45-60 years, at prime age of life

#### **Deadly cancer**

High recurrence rate, poor survival, 80% inoperable



- Surgical resection: 5-year survival 55%, high recurrence rate
- Liver transplantation: best cure with 5-year survival 75%, only for early HCC; limited liver donor availability




## Reactive Oxygen Species & Antioxidants

- Reactive Oxygen Species (ROS)
  - Side-products of oxygen  $(O_2)$  metabolism
- Antioxidants
- Antioxidants are molecules that inhibit ROS
- Vitamin A
  - Milk, egg yolk, carrots
- Vitamin C
  - Fresh vegetables and fruits (orange, lemon, tomato)
- Vitamin E
  - Nuts, whole grains
- Antioxidant supplements contain high dose of antioxidants




### **Oxidative stress**





### **Oxidative stress**



Normal cell


Reactive Oxygen Species (ROS)

**Oxidative stress** 

or Free radicals

Oxidative stress is a disturbance in the balance between the production of ROS and antioxidant defenses.

Image source: http://kangencharge.co.uk/free-radicals-vs-antioxidants/




cancer cells

antioxidants to neutralize ROS

Liver cancer cells





## Liver cancer cells use TKT enzyme in the PPP to produce antioxidant






## **TKT promotes liver cancer growth in mice**







ATC ATA SATATA


15-

0

Total Flux 10<sup>7</sup>(p/s)




## Blocking PPP with chemical, oxythiamine, suppresses liver cancer growth






## **TKT is activated in liver cancer**



B	Case1	Case2	Case3
	NT HCC	NT HCC	NT HCC
ткт	-0		
Actin			
	Case4	Case5	Case6
	Case4	Case5 NT HCC	Case6 NT HCC
ткт			






Higher TKT expression levels in patients' liver cancer are associated with a large cancer size and high spreading (metastatic) ability




## **TKT is also activated in other cancers** (e.g. Colorectal, Lung Cancer)





## **Research Summary**





## **Future studies**

- HKU research team is conducting a further study
  - identify additional anti-oxidant producing pathways in liver cancer
  - evaluate the therapeutic efficacy of drugs against antioxidant-producing pathways in the suppression of liver cancer and the combined effect with chemotherapy
- Aim: develop molecular targets





• Liver cancer patients should have a balanced diet

• High intake of antioxidant supplements may not be beneficial to cancer patients



# Q & A